Skip to main content

Hormonal implants are popular among Europeans but are not available in Canada.

AP

Although Canadian women have access to a wide range of birth control options, there's no one size that fits all. What works for one woman may not work for another, either for personal or cultural or medical reasons.

Other safe, highly effective contraceptives are available to women throughout Europe, South America, Asia and the United States, reproductive health experts say – and Canadian women are missing out.

There's the hormonal implant, popular among teens in Europe, and a more effective mini-pill made by Merck, which has never applied to make it available in Canada. Health Canada's long and stringent approval process for contraceptives may be part of the reason why women's options are more limited here than in other countries.

Story continues below advertisement

Take the hormonal implant, a plastic rod inserted under the skin of the upper arm. The matchstick-sized rod releases progestin for three years, keeping eggs from leaving the ovaries.

Hormonal implants are used in 86 countries, including Australia, Denmark, Germany and Britain. Compared with the pill, implants are cheaper over the long term, easier to use and less likely to result in pregnancy.

The implant is also safe for women who cannot take estrogen. Like IUDs, they are reversible and more than 99-per-cent effective.

So why isn't it available here? Merck, manufacturer of an implant called Nexplanon, recently submitted an application to bring the device to Canada, said Dr. Amanda Black, chair of the contraception awareness program at the Society of Obstetricians and Gynaecologists of Canada. But some of Merck's clinical trial data was not recent enough to satisfy Health Canada, she said.

The device had already been on the market for years, so it wasn't financially feasible for Merck to conduct costly new clinical trials to satisfy the regulatory requirements of a small market such as Canada.

The device is unlikely to enter this country unless the public applies significant pressure on both Merck and Health Canada, Black said. "Basically, it's at an impasse."

Research has shown that unintended pregnancy rates decrease with the use of long-lasting reversible contraceptives such as implants and IUDs. But many teens are wary of IUDs because they're uncomfortable with the idea of having a device inserted into their vaginas, said Dr. Ellen Wiebe, medical director of Willow Women's Clinic in Vancouver.

Story continues below advertisement

A device under the skin is another matter. "My colleagues in Europe say it's the teens who love their implants so much," she said.

Wiebe is one of few Canadian physicians with the skills to remove expired implants from immigrant women who had them inserted elsewhere. "So many of them say, 'I wish I could get my implant [here].'"

Another birth control option available in the U.S. and many European countries, but not in Canada, is Cerazette. The drug is similar to the progestin-only "mini-pill" available here, but is more effective because it doesn't dissipate as quickly in the body. "It's probably a much better pill," Black said.

When she attends meetings with family planning experts in Europe, "they're all shocked that we don't have that one." The pill's manufacturer, Merck, has never applied to bring Cerazette to Canada.

Health Canada approval for contraceptives takes more than two years longer than approval for agents in other drug classes, Black said. This lag time, combined with Health Canada's stringent requirements, may deter manufacturers from submitting applications for new contraceptives, she said. "That limits the options Canadian women have."

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter